hi

Etihad Etisalat Co
the period is yearly

Final Project Guidelines: Computer Application in Finance

Purpose:

The student will develop a financial model. The final project is conducted via
Microsoft Excel, which allows students to test their knowledge and skills. Each team manages all aspects, including company selection, assumptions, and calculations. The goal of the project is to estimate the valuation of a business and to compare companies to their industry competitors.

Instructions

The project will be teamwork, with
2-3 students in each group. Each group will submit only one excel file.

As part of the course requirements, you will use
Microsoft Excel to create your model.

Each group needs to select its company as early as possible. Please note that two groups

cannot
have the same company.
Click here to write the name of your company.

Submission will be
on Sunday, 30th October 2022.

This project weighs
20% of your total grades.

Requirements

1- Select a company from Tadawul, excluding financial sectors, with a minimum of
four years of historical data (
Yr. 2021 should be the latest year).

* Financial Sectors including Banking Industry, Insurance Industry, and Diversified Financials Industry*
2- Forecast the Income statement, Balance Sheet, and Cash Flow Statement for the next
three Years.

3- Complete Common Size Analysis (
including forecasted years).

4- Complete Yr. to Yr. Comparative Analysis (
including forecasted years).

5- Include ratio analysis to help explain how pieces of information relate to one another (
including forecasted years).

6- Calculate the firm value by using at least
2-Valuation Models.

7- Calculate the company’s ROE using the
Du Pont System (
including forecasted years).

8- Calculate the amount of external funding required (
using
sensitivity analysis for forecasted years
).

9- Make sure that you assign one sheet for your input, and the rest of the sheets should be linked to the input sheet.
10- Make your sheets interactive by including Charts and Sparklines (
where required).

image1.png

SHOW MORE…

Answer discussion1

9

answer this discussion based on this:
Critique your colleagues
indicate any therapeutic changes that you might make based on possible outcomes that may happen given your treatment options chosen.
References at least 2-3 no more than 5 years ago.

do not make negative critique

In reviewing the case study of this 75-year-old female who recently suffered the loss of her spouse of 41 years, the three questions that this writer may want to ask are: (1) how have you been doing with taking the medication Sertraline? Although it is not known precisely how long this medication has been prescribed, the case study does reveal that the spouse passed away ten months ago. The patient has a diagnosis of Major Depressive Disorder (MDD). This information will be used to determine whether the medication is taken as prescribed, if at all; depression and insomnia are known to co-exist, but it is not known which comes first, “depression or insomnia” (Brouwer et al., 2022). Also of note, insomnia is a known side effect of the medication Sertraline (
Sertraline: MedlinePlus Drug Information, n.d.). (2) A second question that would be of interest is “how often are alcoholic beverages consumed?” A study of more than 9,000 participants (over 5000> age 60) was conducted on the use of alcohol, MDD, and grief which revealed that changes in alcohol use, whether an increase or decrease, has contributed to insomnia in bereaved individuals, ranging from a few months to a few years after bereavement (Aoyama et al., 2020). (3) It would be essential to ask the individual, “What are your current sleep patterns; is there difficulty going to sleep or staying asleep?” If the individual is sleeping most of the day, it is not uncommon that one would be restless during the night; of course, the question is why?

Individuals with privileged information who may be able to provide insight into this patient’s condition would include a child, caregiver, and a close friend or grief counselor. These individuals may be able to provide insight into the patient’s cognitive functioning, as well as coping mechanisms related to the loss of her spouse. Also, close family and friends may know about other complaints that may not be known to the provider that may be affecting this patient’s ability to sleep. It would be helpful to know what behaviors these individuals have observed and the appetite of the individual. The importance of speaking with others in this individual’s circle is to determine if any other medical, physiological, or psychological conditions may affect this individual’s sleep that has not been previously disclosed.
In determining the cause of this individual’s sleep disturbance, it would be beneficial to gather a good history of present illness, including any heart and lung issues, substance use, pain condition, and psychiatric history, past or present. Workup should include an initial lab screen to include a CBC, CMP, urinalysis, sedimentation rate, thyroid tests, and A1C check. The initial labs could determine if the condition is related to infection or inflammation that may or may not be related to pain, other drug use, or other medical condition causing insomnia (Collins, 2017).
Differential diagnoses related to this individual’s sleep disturbance include prolonged grief, insomnia, nocturia, substance use, Gastrointestinal Esophagus Reflux Disease, depression, and osteoarthritis. Although all the noted differential diagnoses may impact one’s ability to sleep, Garg (2018), this writer believes the patient’s condition is, in fact, Insomnia Disorder due to unresolved depression related to the loss of a spouse.
A pharmacologic agent appropriate for the patient’s antidepressant therapy includes a Serotonin and Norepinephrine Reuptake Inhibitor (SNRI), Cymbalta. The exact mechanism of action of Cymbalta is unknown. However, its use includes the treatment of Major Depressive Disorders (MDD) and treatment of pain. Cymbalta has anxiolytic properties, relieves anxiety, and may raise serotonergic and noradrenergic brain activity. Cymbalta will be started at 30 mg daily for two weeks and, after a follow-up visit, may increase if no improvement or minimal improvement is noted and medication is tolerated; age adjustment for the elderly patient is not necessary for this medication (Cymbalta (Duloxetine Delayed-Release Capsules), n.d.).
Another antidepressant drug appropriate for treating this patient is Tofranil, a Tricyclic Antidepressant (TCA). Like Cymbalta, the mechanism of action for Tofranil is not precisely known, but it is known to stimulate the central nervous system and is effective in treating MDD. The initial starting dose of Tofranil will be 30 mg daily, starting at a lower dose (recommended 30-40 mg/day for elderly patients). The patient will be rechecked in two weeks, and the medication dose will be adjusted as needed, not to exceed 100 mg/day
(Tofranil (Imipramine Hydrochloride), n.d.).

Given the two choices, Cymbalta or Tofranil, this writer would prescribe Cymbalta because there are no drug interactions with medications the patient is already taking, and the medication will effectively treat the patient’s condition; unlike Tofranil, which interacts with medications the patient is already taking. Tofranil has synergistic effects, which interact with Metformin and Januvia, which may cause an increase in the effects of Metformin and Januvia (
Drug Interactions Checker Medscape Drug Reference Database, n.d.). Also worth noting is that the medication Tofranil is contraindicated in an individual that has taken a Monoamine Oxidase Inhibitor (MOAI) recently (within the last 14 days) or is currently using; use may result in an extremely high temperature and seizure. Besides MOAIs, Tofranil may interact with other drugs affecting the enzyme Cytochrome P450, requiring lower doses. Additionally, Tofranil may exacerbate cardiac disease
(Tofranil (Imipramine Hydrochloride), n.d.). As with Tofranil, Cymbalta use is contraindicated if a MOAI’s prior or current use is noted. Moreover, the medication Cymbalta may cause hyponatremia; as well as an increase in blood pressure and glucose; it is recommended to monitor regularly (
Cymbalta (Duloxetine Delayed-Release Capsules), n.d.), which is especially important in this patient with diabetes and hypertension. The desired outcome for this patient is to effectively treat depression while improving the patient’s insomnia and overall improve the patient’s quality of life. This patient will also benefit from grief counseling if not already receiving counseling.

References

Aoyama, M., Sakaguchi, Y., Fujisawa, D., Morita, T., Ogawa, A., Kizawa, Y., Tsuneto, S., Shima, Y., & Miyashita, M. (2020). Insomnia and changes in alcohol consumption: Relation between possible complicated grief and depression among bereaved family caregivers.
Journal of Affective Disorders,
275, 16.
https://doi.org/10.1016/j.jad.2020.06.023

Brouwer, A., van de Ven, P. M., Kok, A., Snoek, F. J., Beekman, A. F., & Bremmer, M. A. (2022). Symptoms of depression and insomnia in older age: A withinindividual analysis over 20years.
Journal of the American Geriatrics Society,
70(7), 20512059.
https://doi.org/10.1111/jgs.17765

Collins MD, Dr. R. Douglas & . (2017).
Algorithmic diagnosis of symptoms and signs(4th ed.). LWW.

Cymbalta (duloxetine delayed-release capsules). (n.d.). U.S. Food and Drug Administration. Retrieved October 11, 2022, from
https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba/spl-doc?hl=cymbalta#section-8.4

Drug interactions checker – Medscape drug reference database. (n.d.). Retrieved October 11, 2022, from
https://reference.medscape.com/drug-interactionchecker

Garg, H. (2018). Role of optimum diagnosis and treatment of insomnia in patients with hypertension and diabetes: A review.
Journal of Family Medicine and Primary Care,
7(5), 876.
https://doi.org/10.4103/jfmpc.jfmpc_337_17

Sertraline: Medlineplus drug information. (n.d.). Retrieved October 11, 2022, from
https://medlineplus.gov/druginfo/meds/a697048.html

Tofranil (imipramine hydrochloride). (n.d.). U.S. Food and Drug Administration. Retrieved October 11, 2022, from
https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/e6aba45c-9e3c-4d14-82ce-fda3ba771fe1/spl-doc?hl=tofranil